dual agonist glp 1 Effects, working principles and target tissues of agonists Clinical Focus on GLP-1 Agonists

These medications exert (in)direct hepatic actions by reducing steatosis, attenuating inflammation, and potentially reversing fibrosis, while simultaneously addressing systemic metabolic abnormalities including excessive obesity, insulin resistance, and cardiovascular risk

Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products

BCBS dropped GLP-1 weight loss drug coverage across multiple states

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide and tirzepatide, have emerged as transformative agents for type 2 diabetes and obesity through their potent effects on weight reduction, insulin sensitivity, and cardiovascular outcomes